Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY
Eli Lilly shares fell 7.8% to $1,020.84 in after-hours trading Thursday after Reuters reported Hims & Hers began selling a $49 compounded version of Novo Nordisk’s Wegovy, raising discount fears in the GLP-1 drug market. Earlier, Lilly posted a 43% jump in quarterly revenue to $19.29 billion, led by Mounjaro and Zepbound, and forecast 2026 sales above Wall Street estimates.